APA (7th ed.) Citation

Baker, J. F., Bakewell, C., Dikranian, A., Lam, G., O'Brien, J., Moore, P. C., . . . Masri, K. R. (2024). Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting. Rheumatology & Therapy, 11(3), 841. https://doi.org/10.1007/s40744-024-00653-6

Chicago Style (17th ed.) Citation

Baker, Joshua F., Catherine Bakewell, Ara Dikranian, Gordon Lam, Jacqueline O'Brien, Page C. Moore, Miao Yu, Peter Hur, and Karim R. Masri. "Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting." Rheumatology & Therapy 11, no. 3 (2024): 841. https://doi.org/10.1007/s40744-024-00653-6.

MLA (9th ed.) Citation

Baker, Joshua F., et al. "Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting." Rheumatology & Therapy, vol. 11, no. 3, 2024, p. 841, https://doi.org/10.1007/s40744-024-00653-6.